Basically they have a way to implant altered cells that produce some desired protein (like EPO).
Roth and Maxim pushed the IPO very hard, but I passed. Interesting science, but too much like a science experiment instead of a viable company for my taste. For long-term protein replacement (hemophilia?) it could be interesting.
They had a deal with Baxter that they "extended" for 6 months at their own cost. I read it that Baxter passed.
Just from that description I would think there are some major issues with regards to scale. That's a 2.5 mL "sliver" that is supposed to produce how many times it's weight in protein *and* guarantee secretion of said protein to the circulation so that it reaches a therapeutic level?
And practically, is this any better for the patient than IV infusion? Or is it just a "novel" way of delivery (scale issues aside)?
So the bio-pump is actually protein-producing tissue harvested from the person's body?
The tissue is taken from the person's body, then the gene sequence is inserted into the tissue, cleaned and then sent back and reinserted into the person.
News 
Market Data 
Discover 
AI
